- Trials with a EudraCT protocol (33)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
33 result(s) found for: Ethics of technology.
Displaying page 1 of 2.
EudraCT Number: 2011-002203-15 | Sponsor Protocol Number: PregMet2 | Start Date*: 2012-08-08 | |||||||||||
Sponsor Name:NTNU, Norwegian University of Science and Technology | |||||||||||||
Full Title: Metformin treatment of pregnant PCOS women and prevention of late miscarriages and preterm birth The PregMet 2 Study | |||||||||||||
Medical condition: Poly Cystic Ovarial Syndrome (PCOS) in pregnant women. PCOS should be diagnosed according to the Rotterdam Consensus criterias: - at least 2 out of 3 criterias 1.PCO in at least one ovary 2.Olig... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: NO (Completed) SE (Completed) IS (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002282-19 | Sponsor Protocol Number: MENAC-2017-03 | Start Date*: 2016-05-17 |
Sponsor Name:Norwegian University of Science and technology | ||
Full Title: A randomised, open-label trial of a Multimodal Intervention (Exercise, Nutrition and Anti-inflammatory Medication) plus standard care versus standard care alone to prevent / attenuate cachexia in a... | ||
Medical condition: cachexia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NO (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-023562-51 | Sponsor Protocol Number: BT-CL-PGG-CRC1031 | Start Date*: 2011-11-17 | |||||||||||
Sponsor Name:Biothera | |||||||||||||
Full Title: A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination with Cetuximab (Erbitux®) in Subjects with Recurrent or Progressive KRAS Wild Type Colorectal Cancer | |||||||||||||
Medical condition: Recurrent or Progressive KRAS Wild Type Colorectal Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005830-63 | Sponsor Protocol Number: 0485-CL-0004 | Start Date*: 2009-10-30 | |||||||||||
Sponsor Name:Astellas Pharma Global Development, Inc. (APGD) | |||||||||||||
Full Title: A Phase 2, Single-Arm Study to Evaluate the Safety and Pharmacokinetics of Alefacept in Adolescent Subjects with Moderate to Severe Psoriasis | |||||||||||||
Medical condition: Moderate to severe chronic plaque psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Prematurely Ended) LV (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-004774-85 | Sponsor Protocol Number: IDEC 102-12 | Start Date*: 2005-04-13 |
Sponsor Name:Biogen Idec Inc | ||
Full Title: A Multicenter Study to Evaluate the Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens | ||
Medical condition: Relapsed (maximum of 5 relapses) or refractory, low-grade or follicular, CD20+, B-cell Non-Hodgkin’s Lymphoma (NHL) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: LT (Completed) GB (Completed) DE (Completed) CZ (Completed) AT (Completed) SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-001648-91 | Sponsor Protocol Number: TRIPLEX | Start Date*: 2021-09-21 | |||||||||||
Sponsor Name:Norwegian University of Science and Technology | |||||||||||||
Full Title: Randomized phase III trial investigating the survival benefit of adding thoracic radiotherapy to durvalumab (MEDI4736) immunotherapy plus chemotherapy in extensive stage small-cell lung cancer | |||||||||||||
Medical condition: Extensive stage small-cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Trial now transitioned) EE (Trial now transitioned) NL (Trial now transitioned) IS (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020137-10 | Sponsor Protocol Number: M11-271 | Start Date*: 2010-09-20 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: An Open-Label, Multicenter, Efficacy and Safety Study to Evaluate Two Treatment Algorithms in Subjects with Moderate to Severe Crohn's Disease | |||||||||||||
Medical condition: Crohn's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) SE (Completed) CZ (Completed) AT (Completed) ES (Completed) FR (Completed) BE (Completed) IT (Completed) NL (Completed) HU (Completed) LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003708-29 | Sponsor Protocol Number: B7981005 | Start Date*: 2017-04-18 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A Phase 2B, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Dose Ranging Study of Oral PF-06651600 and PF-06700841 as Induction and Chronic Therapy in Subjects with Moderate to Severe... | |||||||||||||
Medical condition: Moderate to severe Ulcerative Colitis (UC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) LT (Completed) DK (Completed) DE (Completed) AT (Completed) PL (Completed) HU (Completed) ES (Completed) NL (Completed) BG (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-013112-12 | Sponsor Protocol Number: REGENERATE/DCM/2.0 | Start Date*: 2010-04-22 | |||||||||||
Sponsor Name:Barts & the London NHS Trust | |||||||||||||
Full Title: Randomised Controlled Trial To Compare The effects of G-CSF(Granocyte™) And Autologous Bone Marrow Progenitor Cells On Quality Of Life And Left Ventricular Function In Patients with Idiopathic Dila... | |||||||||||||
Medical condition: Idiopathic Dilated Cardiomyopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003822-42 | Sponsor Protocol Number: B1971048 | Start Date*: 2015-01-30 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A Phase 4, Single-Arm, Open-Label Study describing the safety and immunogenicity of Bexsero in healthy subjects aged 12 years to <19 years. | |||||||||||||
Medical condition: Test the safety and immunogenicity of Bexsero used as a vaccine for Neisseria meningitidis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001218-24 | Sponsor Protocol Number: TDL-CS-001 | Start Date*: 2014-06-05 | |||||||||||
Sponsor Name:Trichocare Diagnostics Ltd | |||||||||||||
Full Title: An open label, intra-subject, controlled multi-centre study to assess the concordance (specificity and sensitivity) between Colourstart® Test 73 mcg Cutaneous Patch and Finn Chamber in the detectio... | |||||||||||||
Medical condition: Para-Phenylenediamine allergy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-015985-75 | Sponsor Protocol Number: HGT-REP-060 | Start Date*: 2010-02-03 | |||||||||||
Sponsor Name:Shire Human Genetic Therapies (HGT), Inc. | |||||||||||||
Full Title: An Open-label Extension of Study TKT028 Evaluating Safety and Clinical Outcomes of Replagal Enzyme Replacement Therapy Administered to Adult Patients with Fabry Disease | |||||||||||||
Medical condition: Fabry disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) CZ (Completed) GB (Completed) FI (Completed) SI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003359-43 | Sponsor Protocol Number: B7981007 | Start Date*: 2018-05-24 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 As Induction And Open Label Extension Treatmen... | |||||||||||||
Medical condition: Moderate To Severe Crohn’s Disease (CD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) DE (Completed) SK (Completed) AT (Completed) PL (Completed) HU (Completed) ES (Completed) CZ (Completed) BE (Completed) HR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005843-40 | Sponsor Protocol Number: PXD101-CLN-19 | Start Date*: 2008-11-11 | |||||||||||
Sponsor Name:Spectrum Pharmaceuticals Inc. | |||||||||||||
Full Title: A Multicenter, Open-Label Trial of Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma | |||||||||||||
Medical condition: Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) FR (Completed) IT (Completed) NL (Completed) BE (Completed) DE (Completed) ES (Completed) HU (Completed) SK (Completed) PL (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021348-16 | Sponsor Protocol Number: HGT-SAN-067 | Start Date*: 2011-02-09 | ||||||||||||||||
Sponsor Name:Shire Human Genetic Therapies, Inc | ||||||||||||||||||
Full Title: An Open-Label Extension of Study HGT-SAN-055 Evaluating Long Term Safety and Clinical Outcomes of Intrathecal Administration of rhHNS in Patients with Sanfilippo Syndrome Type A (MPS IIIA) | ||||||||||||||||||
Medical condition: Sanfilippo Syndrome Type A or Mucopolysaccharidosis (MPS IIIA) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) NL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-002726-84 | Sponsor Protocol Number: SHP607-203 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Premacure AB | |||||||||||||
Full Title: Long-Term Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment with SHP607 in Extremely Premature Infants | |||||||||||||
Medical condition: Chronic Lung Disease | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022897-14 | Sponsor Protocol Number: PreMENAC-2011-01 | Start Date*: 2011-05-02 |
Sponsor Name:Dep. of Cancer Research and Molecular medicine, Norwegian University of Science and Technology | ||
Full Title: PreMENAC: Multimodal Exercise/Nutrition/Anti-inflammatory treatment for Cachexia: A feasibility study (phase II) | ||
Medical condition: Diagnosis of non operable non-small cell lung cancer NSCLC (stage III-IV) or pancreatic cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Completed) GB (Completed) DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-002676-87 | Sponsor Protocol Number: CA209-9TM | Start Date*: 2018-02-23 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Nivolumab or Nivolumab plus Cisplatin, in Combination with Radiotherapy in Participants with Cisplatin Ineligible and Cisplatin Elig... | |||||||||||||
Medical condition: Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) GB (Completed) PL (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005683-41 | Sponsor Protocol Number: RIOTB2015 | Start Date*: 2016-03-16 | |||||||||||||||||||||
Sponsor Name:Sven O. Skouby, Professor, MD, DMSc. Unit of reproductive Medicine, Herlev/Gentofte Hospital | |||||||||||||||||||||||
Full Title: REDUCING THE IMPACT OF OVARIAN STIMULATION - THE RIOT PROJECT RIOT STUDY B: MAPPING THE ENDOCRINE DETERMINANTS OF OVARIAN STIMULATION TO OPTIMIZE OUTCOMES IN FRESH EMBRYO TRANSFER CYCLES ... | |||||||||||||||||||||||
Medical condition: Infertility | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005543-22 | Sponsor Protocol Number: TKT028 | Start Date*: 2008-06-19 | |||||||||||
Sponsor Name:Shire Human Genetic Therapies, Inc. (Shire HGT) | |||||||||||||
Full Title: A Multi-center, Open-Label, Randomized Study Evaluating the Safety and Efficacy of Three Dosing Regimens of Replagal Enzyme Replacement Therapy in Adult Patients with Fabry Disease | |||||||||||||
Medical condition: Fabry Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) GB (Completed) FI (Completed) SI (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
